Omnicell Upgrades Web Portal, Grows In Medication Management
Zacks Investment Research | Aug 16, 2017 10:15PM ET
Medication and supply management and adherence tools provider Omnicell, Inc. (NASDAQ:OMCL) recently advanced its Patient Management Access Portal (PMAP) with four new enhancements to help it improve patient outcome.
Notably, this single, web-based portal hosts functionality to guide and track patient notes, interventions and appointments. It also provides a detailed information on the patients to the respective pharmacist by identifying, preparing and documenting the ongoing patient engagement.
The latest enhancements to the PMAP include Targeted Adherence Interventions for patients, who are new to chronic therapy. Also, there is a Time My Meds dashboard, providing pharmacists with individualized performance snapshots. These enhancements also consist of single sign-on integration with a third party software, helping the pharmasists assist patients with a Medicare plan option and Immunization Solutions to aid in identifying those in need of vaccinations while simplifying a pharmacist’s workflow.
Per Omnicell, all these advancements will together make PMAP a more comprehensive web portal, prompting the pharmacists to provide a personalized care to medically complex patients while maintaining effective services. Further good news is that this initiative will lead to curbing healthcare costs.
Per the data provided by Omnicell, currently more than 30 million Americans are taking five or more maintenance medications daily. However, only half of all chronic-condition patients, who require medications, do not take them as prescribed. This accounts for a 30-50% of all treatment failures and 125,000 deaths annually. With people gradually realizing the importance of medication adherence, the market potential of PMAP-like web portals seems huge. We expect this latest feature-enhancement of PMAP to result in better market adoption of the system.
For most part of the past three months, Omnicell’s share price consistently underperformed the Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.